Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | KDM1A | O60341 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12836827 | 1.00 | SLC9A1 (0.66) | SLC9A1ALDH1A1HDAC4HPGDFFAR1 | |
| SCHEMBL4740282 | 1.00 | SLC9A1 (0.66) | SLC9A1ALDH1A1HDAC4HPGDFFAR1 | |
| SCHEMBL4856112 | 1.00 | SLC9A1 (0.66) | SLC9A1ALDH1A1HDAC4HPGDFFAR1 | |
| SCHEMBL871538 | 1.00 | SLC9A1 (0.66) | SLC9A1ALDH1A1HDAC4HPGDFFAR1 | |
| SCHEMBL5816055 | 1.00 | SLC9A1 (0.66) | SLC9A1ALDH1A1HDAC4HPGDFFAR1 | |
| SCHEMBL7050196 | 1.00 | SLC9A1 (0.66) | SLC9A1ALDH1A1HDAC4HPGDFFAR1 | |
| SCHEMBL1224903 | 1.00 | SLC9A1 (0.66) | SLC9A1ALDH1A1HDAC4HPGDFFAR1 | |
| Hydrochloric Acid SCHEMBL4380280 | 0.98 | SLC9A1 (0.64) | SLC9A1ALDH1A1HDAC4HPGDFFAR1 | |
| Hydrochloric Acid SCHEMBL6388776 | 0.98 | SLC9A1 (0.64) | SLC9A1ALDH1A1HDAC4HPGDFFAR1 | |
| Ammonia Solution, Strong SCHEMBL27604546 | 0.98 | SLC9A1 (0.64) | SLC9A1ALDH1A1HDAC4HPGDFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | claimed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | claimed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | claimed |
| EP-3490986-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2019-06-05 | — | — | EP | claimed |
| EP-2867226-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-14 | — | — | EP | claimed |
| WO-2018019929-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-02-01 | — | — | WO | claimed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | claimed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | claimed |
| EP-2867226-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | claimed |
| WO-2014002051-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | claimed |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240140930-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024073680-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2867226-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002051-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | PDCD1, TP53, CHEK2 | SLC9A1 3936/4885ALDH1A1 564/4885HDAC4 37/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | SLC9A1 4072/4885ALDH1A1 4333/4885HDAC4 3300/4885 |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | SLC9A1 3874/4885ALDH1A1 2262/4885HDAC4 2994/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | SLC9A1 759/4885ALDH1A1 428/4885HDAC4 2022/4885 |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | SLC9A1 580/4885ALDH1A1 1292/4885HDAC4 2325/4885 |
| US-20240140930-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRPH, EPHX1, BCHE | SLC9A1 4066/4885ALDH1A1 423/4885HDAC4 523/4885 |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | SLC9A1 3490/4885ALDH1A1 241/4885HDAC4 1301/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | SLC9A1 759/4885ALDH1A1 428/4885HDAC4 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.